VA Study: Type 2 Diabetes Patients Quitting GLP-1s Face Reversed Weight Loss and Higher Heart Risks
A study published in March 2026 by the VA Saint Louis Healthcare System analyzed more than 330,000 veterans with type 2 diabetes who used GLP-1 medications such as Ozempic. Researchers found that patients who stopped these drugs experienced weight regain and a 22% increase in cardiovascular risks, including strokes and heart failure, due to reversed metabolic benefits, according to lead researcher Dr. Ziyad Al-Aly.
The study, led by Dr. Ziyad Al-Aly of the VA Saint Louis Healthcare System and published in March 2026, examined more than 333,000 veterans with type 2 diabetes who had been treated with glucagon-like peptide-1 receptor agonists (GLP-1s), including medications such as Ozempic. Researchers used comprehensive VA healthcare records to emulate a randomized trial design, following patients for up to three years across 16 different treatment scenarios. These scenarios included continuous use of GLP-1s, discontinuation at various time points, treatment interruptions, and restarts, according to the study details provided by the VA.
Patients who discontinued GLP-1 therapy experienced a 22% increase in major adverse cardiovascular events, including strokes and heart failure, compared with those who maintained continuous treatment.
The findings indicated that patients who discontinued GLP-1 therapy experienced a 22% increase in major adverse cardiovascular events, including strokes and heart failure, compared with those who maintained continuous treatment. Dr. Al-Aly described this phenomenon as “metabolic whiplash,” noting that the reversal of previously gained metabolic benefits contributed to heightened cardiovascular risks. The study reported that the cardiovascular protection built progressively during ongoing GLP-1 use diminished substantially within a few years after stopping the medication.
In addition to increased cardiovascular risks, patients who stopped GLP-1s showed significant weight regain. While weight loss during treatment was visible and measurable, the metabolic reversal following discontinuation manifested as increased insulin resistance, spikes in inflammation, elevated blood pressure, and higher cholesterol levels, according to the research. Dr. Al-Aly emphasized that “weight regain is visible. The metabolic reversal is not,” highlighting the less apparent but clinically significant changes that contribute to worsening heart health.
The study’s methodology relied on VA healthcare records to emulate a randomized controlled trial, a design that allowed researchers to assess real-world outcomes among veterans with type 2 diabetes. The patient population included more than 330,000 adults who were followed longitudinally for cardiovascular outcomes after changes in GLP-1 treatment. Researchers tested 16 treatment scenarios, comparing continuous use with discontinuation, interruptions, and restarts over periods extending up to three years.
According to the data, continuous GLP-1 therapy was associated with progressive cardiovascular benefits, including reductions in heart disease and stroke risks. The protection appeared to build over time with consistent use, underscoring the potential long-term benefits of maintaining treatment. Conversely, the discontinuation of GLP-1s reversed these protective effects, leading to a significant increase in cardiovascular events and metabolic complications.
The study also documented a notable increase in inflammatory markers following cessation of GLP-1 medications, which researchers linked to elevated risks of heart failure and stroke. Elevated blood pressure and cholesterol levels were observed alongside worsening insulin resistance, factors that collectively contributed to the heightened cardiovascular risk profile among patients who stopped GLP-1 therapy.
Dr. Al-Aly stated, “We think of this as a form of metabolic whiplash, and our data suggest it is detrimental to heart health.” He further explained that while weight regain is an obvious consequence of stopping GLP-1s, the underlying metabolic changes that increase cardiovascular risk are less visible but equally important. The research team concluded that the risks associated with discontinuing GLP-1 medications outweigh the potential benefits of stopping treatment.
The VA Saint Louis Healthcare System’s study adds to a growing body of evidence supporting the cardiovascular and metabolic benefits of GLP-1 receptor agonists in patients with type 2 diabetes. These medications have been shown to reduce body weight and adiposity effectively while improving insulin sensitivity and lowering inflammation during active treatment periods. The research underscores the importance of continuous therapy to sustain these benefits and prevent reversal of metabolic gains.
This study’s findings have implications for clinical management of type 2 diabetes, particularly in veteran populations who often face complex comorbidities. The comprehensive VA healthcare records allowed for robust real-world evidence, capturing diverse treatment patterns and long-term outcomes. The research team’s use of an emulated randomized trial design strengthens the validity of the findings, providing actionable data for healthcare providers and policymakers.
Further research may explore strategies to mitigate the metabolic and cardiovascular risks associated with GLP-1 discontinuation, as well as patient factors influencing adherence to long-term therapy. The VA Saint Louis Healthcare System continues to analyze data to better understand treatment patterns and outcomes in this high-risk population.
